An Indian national survey of therapeutic drug monitoring with anti-tumor necrosis (TNF) medications in inflammatory bowel disease.
Rajan N PatelGaurav B NigamRaj G JataleDevendra DesaiGovind MakhariaVineet AhujaJimmy K LimdiPublished in: Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology (2020)
Significant barriers to TDM use were availability, cost and time lag for results. If these barriers were removed, almost all the clinicians would use TDM at least reactively and 25% would use proactively. There is an urgent need to address these barriers and optimize anti-TNF therapy for optimal outcomes.